Dr. Kaeberlein's Optispan Podcast Series - Rapamycin and More

#121
2 Likes
#122

Everything I do for Healthspan (and why I skip THESE Supplements)

Gemini Pro Video Summary:

Here is the summary and analysis of the provided transcript.

A. Executive Summary

In this episode of the Optispan podcast, the host (Matt Kaeberlein) details his personal health protocol as of late 2025, covering lifestyle pillars, supplements, and pharmaceutical interventions. His core philosophy emphasizes a strict hierarchy of efficacy: Foundational Lifestyle Pillars (Eat, Move, Sleep, Connect) provide the vast majority of health benefits, followed by targeted medications, with supplements ranking a distant third due to weak regulatory oversight and inconsistent efficacy.

Regarding lifestyle, he adheres to a whole-food diet minimizing added sugars, engages in daily Zone 2 cardio and resistance training 3-4 times per week, and prioritizes sleep hygiene by eliminating alcohol. He identifies “Connection” as his weakest pillar but is actively working on relationship building.

His supplement strategy is highly skeptical. He utilizes a small stack including Omega-3, Vitamin D, Calcium Alpha-Ketoglutarate (Ca-AKG), Methylfolate, Lithium Orotate, and Creatine. He explicitly rejects popular “hype” supplements such as NAD+ precursors, Resveratrol, and general antioxidants, citing a lack of compelling clinical data or potential counter-productivity.

On the pharmaceutical front, he employs a preventative, risk-reward approach. He utilizes Testosterone Replacement Therapy (TRT) for quality of life and Rapamycin (cyclic dosing) for longevity/geroprotection. Notably, he uses SGLT2 inhibitors (Jardiance) and PCSK9 inhibitors (Repatha) for metabolic and cardiovascular prophylaxis, arguing that SGLT2s have superior longevity data (in mice) compared to Metformin, which he has discarded. He advocates for finding physicians willing to engage in proactive, preventative risk assessment rather than reactive disease management.

B. Bullet Summary

  • Hierarchy of Health: Lifestyle modifications (diet, exercise, sleep) are the primary drivers of healthspan; supplements are mostly incremental or “noise.”
  • Nutritional Rule #1: Religiously read labels to avoid added sugars; prioritize fiber (e.g., keto bread) and high-quality protein (salmon, poultry).
  • Training Volume: Daily activity is non-negotiable. 30 minutes of Zone 2 cardio daily, plus resistance training 3-4 times per week focusing on compound movements.
  • Alcohol Elimination: Alcohol is identified as a primary disruptor of sleep quality; removing it is a high-yield intervention.
  • Supplement Skepticism: The supplement industry is described as “dishonest and deceptive.” Third-party testing (e.g., ConsumerLab) is essential for purity.
  • Creatine Utility: Recommended for everyone (5g/day) for muscle mass preservation and potential cognitive benefits (buffering energetic stress in the brain).
  • Lithium for Brain Health: Low-dose Lithium Orotate (5mg) is added based on epidemiological data linking trace lithium to reduced Alzheimer’s risk.
  • SGLT2 over Metformin: Metformin is dismissed for longevity in healthy individuals due to failure in the Interventions Testing Program (ITP); SGLT2 inhibitors (Jardiance) are preferred for their lifespan extension data in mice.
  • Lipid Management: Soft plaque detection prompted the use of Repatha (PCSK9 inhibitor) to aggressively lower ApoB, superior to statins for this specific profile.
  • Rapamycin Protocol: Adheres to a cyclic protocol (e.g., 8mg/week for 3 months on, followed by a washout period) to mitigate immune risks while targeting sterile inflammation.
  • Testosterone Micro-dosing: Switched from weekly to daily TRT injections (6 days/week) to mitigate hematocrit spikes and stabilize serum levels.
  • GLP-1/GIP Agonists: Experimented with low-dose Tirzepatide (Zepbound/Mounjaro); noted appetite suppression and weight loss but discontinued to assess baseline.
  • Preventative Cardiology: Standard lipid panels are insufficient; specifically measure ApoB and utilize coronary CT angiograms with contrast to detect soft plaque.

D. Claims & Evidence Table

Claim Evidence Cited Assessment
Alcohol disrupts sleep quality. Personal biometrics (wearables) and observations of patients/clients. Strong (Supported by broad consensus and sleep architecture data).
SGLT2 inhibitors (e.g., Canagliflozin) extend lifespan. Murine studies from the Interventions Testing Program (ITP). Strong (in mice); Speculative but plausible for human longevity.
Metformin is NOT a longevity drug for healthy individuals. Failure to extend lifespan in ITP mouse studies; lack of human data outside of diabetics. Strong (Contradicts the TAME trial hypothesis but aligns with rigorous animal data).
Creatine benefits brain health. Emerging evidence on energetic buffering during cognitive stress/sleep deprivation. Speculative/Promising (Plausible mechanism, clinical data still maturing).
Lithium Orotate reduces Alzheimer’s risk. Epidemiological correlation (water supply) and recent biochemical papers (e.g., Bruce Yankner’s lab). Speculative (Strong correlation, mechanism identified, but lacks RCTs).
Ca-AKG reduces biological age/frailty. Mouse studies (frailty reduction) and anecdotal exercise tolerance (Brian Kennedy). Mixed (Good for healthspan/frailty in mice; lifespan data is weak).
Tadalafil lowers all-cause mortality. UK Biobank data analysis. Strong Association (Correlation exists, likely due to circulatory/cardiovascular benefits).

E. Actionable Insights

  1. Stop “Hacking” & Start “Stacking” Pillars: Focus 90% of effort on Eat, Move, Sleep, and Connect. Do not rely on supplements to fix lifestyle deficits.
  2. Eliminate Added Sugars: Scrutinize nutrition labels. If it has added sugar, do not bring it into the house.
  3. Monitor ApoB, Not Just LDL: Request ApoB testing in your quarterly blood panels for a true measure of atherogenic particle burden.
  4. Consider Coronary CT Angiogram: If over 40, consider a scan to detect soft plaque, which traditional calcification scans (CAC) miss.
  5. Micro-dose Creatine: Take 5g of Creatine Monohydrate daily, regardless of whether you lift weights, for potential neuroprotective effects.
  6. Zone 2 is Daily Hygiene: Treat 30 minutes of low-intensity cardio (Zone 2) as a daily requirement, similar to brushing teeth.
  7. Optimize TRT Frequency: If on Testosterone Replacement Therapy, consider daily or every-other-day micro-dosing to prevent hematocrit spikes and estrogenic side effects.
  8. Evaluate SGLT2 Inhibitors: Discuss SGLT2 inhibitors (like Empagliflozin) with your doctor for glucose management and potential geroprotection instead of Metformin.
  9. Check Supplement Purity: Use services like ConsumerLab.com to verify that your supplements do not contain heavy metals or impurities.
  10. Cycle Rapamycin: If using Rapamycin off-label, consider a cyclic approach (e.g., 3 months on, 3 months off) to balance mTOR inhibition with immune function.

H. Technical Deep-Dive

1. SGLT2 Inhibitors vs. Metformin (Geroprotection Mechanisms)
The speaker prioritizes Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors (e.g., Empagliflozin, Canagliflozin) over Metformin.

  • Mechanism: SGLT2 inhibitors block glucose reabsorption in the proximal tubule of the kidney, inducing glycosuria (excretion of glucose in urine) and natriuresis. This lowers plasma glucose and insulin levels independent of insulin secretion.
  • Longevity Data: The Interventions Testing Program (ITP) demonstrated that Canagliflozin extends median lifespan in male mice significantly. Conversely, Metformin failed to consistently extend lifespan in ITP heterogenous mouse cohorts, suggesting its “anti-aging” reputation may be an artifact of treating metabolic dysfunction rather than slowing fundamental aging.

2. Lithium Orotate & Neuroprotection

  • Mechanism: Lithium is a potent inhibitor of Glycogen Synthase Kinase-3 beta (GSK-3β). Hyperactive GSK-3β is implicated in the hyperphosphorylation of Tau protein (leading to neurofibrillary tangles in Alzheimer’s) and the production of amyloid-beta.
  • Dosing: The speaker uses 5mg (micro-dose) compared to psychiatric doses (900mg+). The hypothesis is that chronic, low-grade inhibition of GSK-3β via trace lithium mimics the epidemiological benefits seen in populations with naturally high lithium water content.

3. PCSK9 Inhibition (Repatha)

  • Mechanism: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors (LDLR) on hepatocytes, promoting their lysosomal degradation. By inhibiting PCSK9, Repatha increases the recycling of LDLRs to the cell surface, drastically increasing the clearance of LDL particles (and thus ApoB) from the bloodstream. This is a more targeted and potent mechanism for lowering atherogenic burden than HMG-CoA reductase inhibitors (statins).

I. Fact-Check Important Claims

Claim: “Metformin extends lifespan in diabetics but not non-diabetics.”

  • Status: Contested/Likely Accurate.
  • Analysis: The original Bannister et al. (2014) study suggested diabetics on Metformin lived longer than non-diabetics. However, subsequent analyses have suggested this was due to selection bias (immortal time bias) and rigorous controls do not show lifespan extension in healthy subjects. The ITP data in mice supports the speaker’s skepticism regarding Metformin as a general geroprotector.

Claim: “Creatine has cognitive benefits beyond muscle.”

  • Status: Supported by Emerging Evidence.
  • Analysis: Systematic reviews indicate Creatine supplementation can improve short-term memory and intelligence/reasoning in healthy individuals, particularly under conditions of stress or sleep deprivation.
  • Reference: Avgerinos et al. (2018), Experimental Gerontology.

Claim: “Rapamycin extends lifespan in mice.”

  • Status: Consensus Fact.
  • Analysis: Rapamycin is the most robust pharmacological intervention for lifespan extension in mice, reproducible across multiple sites (ITP), strains, and genders. It functions via inhibition of mTORC1 (mechanistic target of rapamycin complex 1), a central regulator of cell growth and metabolism.
5 Likes
#124

Whether or not it has any protection from Alzheimer’s (it probably does), it certainly raised the anger threshold in me, and that in and of itself is a benefit for me. Anger reliably raises both cortisol and blood pressure. So, low-dose lithium could extend the lifespan of some people.

Repeated blood pressure surges and higher BP variability track with higher mortality

Even when a person’s average BP isn’t terrible, greater variability (big ups/downs across visits, days, or home readings) is associated with higher risk of stroke, coronary disease, and all-cause mortality in meta-analyses and large cohorts.

Ref1

2 Likes
#125

Matt talks about this forum just after the 50 minute mark in this video :+1:

5 Likes
#126

Preventive Failure: How Modern Healthcare Misses Disease Early

Gemini AI Video Summary and Analysis:

Here is the summary and analysis of the provided transcript.

Optispan Podcast: The Clinical Reality of Healthspan Medicine

Host: Matt Kaeberlein | Guest: Dr. Nikki Byrne (Clinical Director, Optispan)

A. Executive Summary

This conversation explores the operational definition of “Healthspan Medicine” as distinct from traditional “reactive disease care.” Dr. Nikki Byrne argues that the standard medical model is fundamentally misaligned with longevity; it allocates resources to crisis management (e.g., stroke rehabilitation) rather than upstream prevention. A central thesis is that “reference range” does not equal “optimal.” The discussion highlights that standard primary care often misses early pathology—such as insulin resistance or carotid plaque—because it relies on lagging indicators like A1C or basic lipid panels.

The Optispan model, as detailed by Byrne, utilizes a “Gateway Day” involving comprehensive diagnostics: advanced blood panels (ApoB, fasting insulin), Point of Care Ultrasound (POCUS), DEXA scans for visceral fat, genetic screening (APOE, MTHFR), and functional movement assessments. The dialogue emphasizes that granular data allows for precise pharmacological and lifestyle interventions. Byrne defends the use of off-label pharmacotherapies for prevention in high-risk but “clinically normal” phenotypes, including GLP-1 agonists for visceral fat reduction in non-obese patients, SGLT2 inhibitors for glucose modulation, and PCSK9 inhibitors for aggressive lipid lowering. The conversation concludes with a critique of the longevity industry’s extremes—specifically dangerous hormone protocols for the elderly—while advocating for a data-driven, patient-autonomous approach to extending healthspan.

B. Bullet Summary

  • The Reactive Trap: The current healthcare system offers minimal interaction (one visit/year) until a catastrophic event occurs, at which point resources become unlimited but often too late to reverse decline.
  • Reference Range vs. Optimal: A patient can have “normal” LDL and A1C but still possess significant carotid plaque and insulin resistance; standard reference ranges are population averages, not health targets.
  • Insulin as a Sentinel: Fasting insulin is a superior early warning marker compared to Hemoglobin A1C. A1C is a lagging indicator; the body can compensate with hyperinsulinemia for years before blood glucose rises.
  • Visceral Adiposity (TOFI): “Thin Outside, Fat Inside” is a critical phenotype. Individuals with normal BMI but high visceral fat (detected via DEXA) are at high metabolic risk.
  • The Utility of GLP-1s: Byrne utilizes GLP-1 agonists (e.g., Tirzepatide) not just for obesity, but to specifically target visceral fat and inflammation in metabolically unhealthy normal-weight individuals.
  • SGLT2 Inhibitors for Longevity: These diabetes drugs (e.g., Empagliflozin) are used off-label for pre-diabetes and potential lifespan extension, citing animal data (ITP) and kidney/CV protection in humans.
  • Aggressive Lipid Management: When statins are insufficient or untolerated, PCSK9 inhibitors (Repatha) are used to crush ApoB/LDL levels to prevent plaque accumulation, even in primary prevention contexts.
  • Diagnostic Imaging: Point of Care Ultrasound (POCUS) is essential for screening thyroid nodules, fatty liver, and carotid intimal thickness, identifying risks missed by blood work.
  • Oral-Systemic Link: Intraoral scanning is included because periodontal inflammation is strongly correlated with cardiovascular disease and dementia risk.
  • Sleep Quality over Quantity: Using tracking (Oura), the focus shifts to deep and REM sleep duration rather than just time in bed; alcohol is identified as a primary disruptor of sleep architecture.
  • Rapamycin Protocol: Used cyclically (e.g., weekly) for longevity. The clinical view is that the risk profile at low doses is minimal compared to the potential upside for immune and geroprotective effects.
  • Creatine Utility: Recommended for men and women (especially post-menopausal) for muscle maintenance and emerging evidence of cognitive support.
  • Patient Autonomy: The clinic supports patient experimentation (e.g., specific peptides) if the safety profile is acceptable, prioritizing the therapeutic alliance over paternalism.

C. Technical Deep-Dive

1. Insulin Resistance & Hyperinsulinemia

Byrne highlights the discrepancy between A1C and Fasting Insulin. Mechanistically, insulin resistance manifests as the downregulation of insulin receptors or defects in the PI3K/AKT signaling pathway in peripheral tissues (muscle, adipose).

  • The Lag: To maintain euglycemia (normal blood sugar), pancreatic -cells undergo hypertrophy and hyper-secrete insulin (compensatory hyperinsulinemia).
  • Clinical Consequence: Standard care measures glucose/A1C, which only elevate after -cell compensation fails. Measuring fasting insulin identifies the metabolic dysfunction years prior to Type 2 Diabetes diagnosis.

2. PCSK9 Inhibition (Repatha)

The podcast discusses using Repatha for patients with high Lp(a) or resistant LDL.

  • Mechanism: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors (LDLR) on the hepatocyte surface, promoting their lysosomal degradation.
  • Intervention: Monoclonal antibodies (Evolocumab) bind PCSK9, preventing it from binding LDLR. This increases LDLR recycling to the cell surface, enhancing the clearance of LDL-C from the plasma.

D. Claims & Evidence Table (Adversarial Peer Review)

Role: Longevity Scientist / Peer Reviewer.
Standard: Strict evidence hierarchy.

Claim from Video Speaker’s Evidence Scientific Reality (Best Available Data) Evidence Grade Verdict
“Fasting insulin is superior to A1C for early detection.” Clinical observation of normal A1C in insulin-resistant patients. Supported. The Kraft patterns demonstrate hyperinsulinemia precedes hyperglycemia by years. (Crofts et al., Diabesity, 2016). B/C Strong Support
“Oral health (gum inflammation) correlates with heart disease/dementia.” Mention of emerging data. Supported (Correlation). High-quality cohort studies link periodontitis to atherosclerotic CVD and Alzheimer’s. Causation via systemic inflammation is the leading hypothesis. (Hastings et al., Alzheimers Dement, 2021). C Plausible
“GLP-1s reduce visceral fat in non-obese (‘skinny fat’) people.” Clinical practice/observation. Translational Gap. Strong data exists for obese populations (SURMOUNT/STEP trials). Data for lean individuals with visceral adiposity is mechanistically sound but lacks specific RCTs. E Speculative (in this population)
“SGLT2 inhibitors (Jardiance) increase longevity.” Cites mouse data; human kidney/CV benefits. Mixed. NIA ITP confirmed lifespan extension in male mice (Miller et al., 2020). Human data shows reduced CV mortality and renal decline (EMPA-REG), but “aging” reversal is unproven in humans. D (Mice) / A (CV Mortality) Plausible (for CV protection)
“Low-dose Lithium (Orotate) is safe/beneficial.” Cites Nature paper; groundwater studies. Speculative. Microdose lithium (1-5mg) is likely safe (unlike psychiatric doses). Longevity benefits are based on epidemiological groundwater correlations and worm/fly studies. Human RCTs for aging are absent. C/D Experimental
“Topical Rapamycin reverses skin aging.” Cites pilot study. Emerging. A small RCT (Chung et al., 2019) showed reduced p16INK4a (senescence marker) and improved collagen. Sample size was small (n=36). B (Small RCT) Plausible
“Gallery Test false positive rate is 50%.” Cites general stats/NYT article. Accurate. In the PATHFINDER study, the Positive Predictive Value (PPV) was approximately 38-43%. A positive result is more likely to be false than true in asymptomatic screening. B Factually Correct
“Hormones of a 25-year-old in an 80-year-old are dangerous.” Clinical judgment/physiology. Consensus Support. High-dose systemic HRT in elderly women well past menopause is linked to increased risk of stroke/VTE (WHI re-analysis). A Strong Support

E. Actionable Insights (Pragmatic & Prioritized)

Top Tier (High Confidence / Standard of Care +)

  1. Diagnostic Upgrade: Do not settle for a standard lipid panel. Demand ApoB and Lp(a) testing once to assess genetic risk.
  2. Metabolic Sentinel: Measure Fasting Insulin alongside glucose. If A1C is normal but Insulin is >5-7 uIU/mL, intervene immediately.
  3. Visceral Fat Check: BMI is insufficient. Use DEXA to identify visceral adipose tissue (VAT). Even if thin, high VAT requires lifestyle or pharmacological intervention.
  4. Periodontal Care: Treat flossing and dental hygiene as cardiovascular prevention.
  5. Sleep Hygiene: Eliminate alcohol within 3-4 hours of bed. Prioritize deep sleep windows (early night) by maintaining consistent bedtimes.

Experimental / Optimization (Risk/Reward Managed)

  1. Creatine Monohydrate (5g/day): Low downside. Benefits muscle preservation and likely cognitive function, particularly during sleep deprivation or menopause.
  2. SGLT2 Inhibitors (e.g., Empagliflozin): Consider off-label use for pre-diabetes or longevity if renal function allows, monitoring for UTIs and hypotension.
  3. GLP-1 Agonists (Low Dose): For “TOFI” (Thin Outside Fat Inside) phenotypes, consider low-dose intervention to strip visceral fat, even if not clinically obese.
  4. Rapamycin (Cyclic): Weekly low-dose protocols (e.g., 6mg/week) for geroprotection. Strict Requirement: Must be done under physician supervision to monitor lipids, glucose, and immune function.

Avoid

  • “25-Year-Old Hormones” after 65: Avoid aggressive, high-dose hormone replacement therapies that aim to mimic youth levels in elderly physiology, specifically regarding estrogen/progesterone in women decades past menopause due to stroke/clotting risk.

I. Fact-Check: Important Claims

Claim: “A patient had a normal lipid panel but significant plaque on ultrasound.”

  • Verification: This highlights the discordance between LDL-C and atherosclerotic risk. Approximately 50% of heart attacks occur in people with “normal” LDL levels. Plaque burden (measured by CCTA or Ultrasound) is the direct disease substrate, whereas LDL is a probabilistic risk factor.
  • Correction: None needed. This aligns with current cardiology consensus moving toward imaging-guided prevention (SCCT guidelines).

Claim: “Magnesium helps with sleep and bowel function.”

  • Verification: Magnesium Glycinate or Threonate is often used for sleep/anxiety, while Magnesium Citrate/Oxide is osmotic and aids bowel movement.
  • Nuance: The transcript doesn’t specify the form, but the physiological claim is accurate depending on the chelation used.

Claim: “Oura ring detects sleep staging accuracy.”

  • Verification: While Oura and other wearables are excellent for patterns and duration, their accuracy in distinguishing specific sleep stages (REM vs. Deep) compared to Polysomnography (PSG) is generally 60-65%.
  • Context: Dr. Byrne correctly notes they use it for “pattern recognition” rather than medical diagnosis, acknowledging the limitations.
3 Likes